Search results
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $94.00 at Needham & Company LLC
ETF DAILY NEWS· 4 days agoThe brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ITCI. Bank of America increased their target < ...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 20 hours agoAs a teenager growing up in northeastern Pennsylvania, she saw numerous neurologists and tried a...
Taysha Gene Therapies (NASDAQ:TSHA) Given Overweight Rating at Cantor Fitzgerald
ETF DAILY NEWS· 4 days agoCantor Fitzgerald’s target price suggests a potential upside of 135.69% from the company’s current price. JMP Securities restated a “market outperform” ...
uniQure director Balachandran Madhavan sells shares worth over $11k By Investing.com
Investing.com· 6 days agoIn a recent transaction, uniQure N.V. (NASDAQ:QURE) Director Balachandran Madhavan sold 2,231 shares...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 7 days agoOn Monday, Piper Sandler shifted its stance on Fate Therapeutics (NASDAQ:FATE) stock, raising the...
ICU Medical, Inc. (NASDAQ:ICUI) Receives $127.00 Consensus Target Price from Analysts
ETF DAILY NEWS· 4 hours agoOne research analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. Needham & Company LLC began coverage on ICU Medical in a report ...
FDA’s Sarepta decision could represent ‘new way of thinking’ for agency - Boston Business Journal
The Business Journals· 9 hours agoThe U.S. Food and Drug Administration’s recent decision to expand approval for a Cambridge company’s controversial gene therapy could signal a changing approach to how the ...
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst - Legend...
Benzinga· 7 days agoShares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being...
Nurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from Needham & Company LLC
ETF DAILY NEWS· 6 days agoRoyal Bank of Canada upped their price objective on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the company an outperform rating in a report on Thursday, April ...
Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $164.00
ETF DAILY NEWS· 6 days agoUBS Group upped their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday ...